Toll-like receptor 3 activation enhances antitumor immune response in lung adenocarcinoma through NF-κB signaling pathway
TLR3 enhances the anti-tumor immune response in LUAD by modulating NF-κB signaling and PD-L1 expression, making it a promising prognostic biomarker and therapeutic target. This study highlights the potential of TLR3 to improve immunotherapy outcomes, providing a comprehensive analysis of its role in LUAD and paving the way for novel therapeutic strategies targeting TLR3-mediated pathways.
Authors
- Hongjiao Wu (ORCID: https://orcid.org/0000-0002-6088-1941)
- Zhi Zhang
- Margaret Liu (ORCID: https://orcid.org/0000-0002-4617-9750)
- Xuemei Zhang (ORCID: https://orcid.org/0000-0003-0705-4231)
- Xiyao Liu (ORCID: https://orcid.org/0000-0002-9827-1655)
- Man Luo (ORCID: https://orcid.org/0000-0003-2393-102X)
- Ang Li (ORCID: https://orcid.org/0000-0002-9802-9359)
Institutions
- North China University of Science and Technology (CN)
- Tangshan Gongren Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-08
- DOI
- https://doi.org/10.3389/fimmu.2025.1585747
- Citations
- 3
- Primary Topic
- Immune Response and Inflammation
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- Wu Jieping Medical Foundation